When will apotex's ruxolitinib generic launch in the us?

When will Apotex’s ruxolitinib generic launch in the US?

The provided information does not state a launch date for Apotex’s ruxolitinib generic in the US.

What determines a generic ruxolitinib launch date in the US?

US generic drug launches are typically driven by FDA approval timing and patent/exclusivity status for the reference product, including whether the generic can market immediately after approval or is blocked until certain legal or regulatory triggers clear. Without the specific FDA approval or legal/patent timeline for Apotex’s product, a launch date can’t be determined from the information given [1].

Which ruxolitinib product and strength is Apotex seeking to launch?

Different ruxolitinib strengths and formulations can have different regulatory milestones. The launch timing also depends on the exact product (strength, formulation, and whether it is an ANDA for oral tablets), none of which are included in the provided information [1].

Is Apotex’s ruxolitinib generic actually approved yet by the FDA?

A generic can only launch after it has FDA approval for marketing in the US. The provided information does not indicate whether Apotex has received FDA approval or when that approval occurred [1].

Sources

[1] No source details were provided with the question, so there is not enough information to determine Apotex’s ruxolitinib generic launch date in the US.